|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,75,200.00 KRW | +1.21% |
|
-4.58% | +1.64% |
| 07/07 | Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA | MT |
| 03/07 | South Korean Shares Jump on Bargain-Hunting, Chip Stock Gains | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biopharmaceutical | 1,61600Cr | 1,93700Cr | 1,87300Cr | 6,07000Cr | 6,03300Cr | |||||
D&A | 17TCr | 18TCr | 19TCr | 39TCr | 25TCr | |||||
Operating Income | 71TCr | 62TCr | 64TCr | 1,19900Cr | 1,21500Cr | |||||
Pharmaceutical Products | ||||||||||
Chemical Drugs | 56TCr | 65TCr | 50TCr | 53TCr | 56TCr | |||||
D&A | 4.61TCr | 5.11TCr | 5.38TCr | 3.55TCr | 3.81TCr | |||||
Operating Income | 5.75TCr | 3.46TCr | 2.79TCr | 918.41Cr | 2.37TCr | |||||
Other | 305.44Cr | 387.71Cr | 514.33Cr | 582.46Cr | 673.74Cr | |||||
D&A | 28Cr | 30Cr | 24Cr | 26Cr | 26Cr | |||||
Operating Income | 22Cr | 29Cr | 45Cr | 51Cr | 8.62Cr | |||||
Intersectoral Insider Transaction Reconciliation | -26TCr | -31TCr | -20TCr | -3,05000Cr | -2,43400Cr | |||||
D&A | -32Cr | -30Cr | -309.62Cr | -401.75Cr | -355.64Cr | |||||
Operating Income | -1.71TCr | -529.92Cr | -1.52TCr | -72TCr | -7.04TCr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
South Korea | 2,01500Cr | 2,32400Cr | 2,26200Cr | 4,18400Cr | 3,52600Cr | |||||
Total Assets | 2,16000Cr | 2,34100Cr | 14,25800Cr | 10,03100Cr | 10,18300Cr | |||||
Europe | - | - | - | 1,86200Cr | 2,14500Cr | |||||
Total Assets | - | - | 19TCr | 78TCr | 80TCr | |||||
Total Assets | - | - | 347.79Cr | - | - | |||||
Total Assets | - | - | 171.74Cr | - | - | |||||
North America | - | - | - | 17TCr | 42TCr | |||||
Total Assets | - | - | 790.85Cr | 3,96400Cr | 4,35900Cr | |||||
Asia | 7.64TCr | 14TCr | 12TCr | 25TCr | 34TCr | |||||
Total Assets | 31TCr | 30TCr | 12TCr | 12TCr | 9.72TCr | |||||
Latin America | - | - | - | - | 16TCr | |||||
Total Assets | - | - | - | 9.23TCr | 9.35TCr | |||||
Central and South America | - | - | - | 14TCr | - | |||||
Americas | 8.46TCr | 13TCr | - | - | - | |||||
Total Assets | 21Cr | - | - | - | - | |||||
Overseas | - | - | - | - | - | |||||
Consolidation Adjustment | -26TCr | -31TCr | -20TCr | -3,05000Cr | -2,43400Cr | |||||
Total Assets | -598.16Cr | -1.11TCr | -2.21TCr | -3.66TCr | -4.98TCr |
- Stock Market
- Stocks
- A068270 Stock
- Financials Celltrion, Inc.
- Business Segments
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition